Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Therapy for TM4SF1- and EpCAM-positive Solid Tumors
NCT04151186Phase 1Unknown
- Sponsor
- Su Haichuan
- Start
- Nov 2019
- Primary completion
- May 2021
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of TM4SF1-directed chimeric antigen receptor T cells and CAR-T EpCAM in pancreatic cancer (PC), colorectal cancer (CRC), gastric cancer (GC) and 1 more, sponsored by Su Haichuan. Primary endpoint: Incidence of Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) at 2 years. Status: unknown.
02
Drugs
TM4SF1-directed chimeric antigen receptor T cellsCAR-T EpCAM
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)gastric cancer (GC)lung cancer
Beyond the preview
Go deeper on NCT04151186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04151186.